Obesity management in adults: a review

A Elmaleh-Sachs, JL Schwartz, CT Bramante… - Jama, 2023 - jamanetwork.com
Importance Obesity affects approximately 42% of US adults and is associated with increased
rates of type 2 diabetes, hypertension, cardiovascular disease, sleep disorders …

What is the pipeline for future medications for obesity?

E Melson, U Ashraf, D Papamargaritis… - International Journal of …, 2024 - nature.com
Obesity is a chronic disease associated with increased risk of obesity-related complications
and mortality. Our better understanding of the weight regulation mechanisms and the role of …

Semaglutide in patients with obesity-related heart failure and type 2 diabetes

MN Kosiborod, MC Petrie, BA Borlaug… - … England Journal of …, 2024 - Mass Medical Soc
Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial

LJ Aronne, N Sattar, DB Horn, HE Bays, S Wharton… - Jama, 2024 - jamanetwork.com
Importance The effect of continued treatment with tirzepatide on maintaining initial weight
reduction is unknown. Objective To assess the effect of tirzepatide, with diet and physical …

Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk

BA Bergmark, NA Marston, TA Prohaska… - … England Journal of …, 2024 - Mass Medical Soc
Background Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains
an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger …

Prevention of cardiorenal complications in people with type 2 diabetes and obesity

DJ Drucker - Cell Metabolism, 2024 - cell.com
Traditional approaches to prevention of the complications of type 2 diabetes (T2D) and
obesity have focused on reduction of blood glucose and body weight. The development of …

The role of lifestyle modification with second-generation anti-obesity medications: comparisons, questions, and clinical opportunities

TA Wadden, AM Chao, M Moore, JS Tronieri… - Current obesity …, 2023 - Springer
Abstract Purpose of Review This review examines lifestyle modification for obesity
management with the goal of identifying treatment components that could support the use of …

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

G Targher, CD Byrne, H Tilg - Gut, 2024 - gut.bmj.com
Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic
liver disease globally and is currently estimated to affect up to 38% of the global adult …

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

DH Ryan, I Lingvay, J Deanfield, SE Kahn, E Barros… - Nature medicine, 2024 - nature.com
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major
adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease …

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

CW le Roux, O Steen, KJ Lucas, E Startseva… - The Lancet Diabetes & …, 2024 - thelancet.com
Background Obesity is a widespread and chronic condition that requires long-term
management; research into additional targets to improve treatment outcomes remains a …